Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1036 to 1050 of 1422 results for social care

  1. Public board meeting agenda and papers: December 2023

    Agenda and papers of the NICE public board meeting on 13 December 2023

  2. Public board meetings

    Agenda and papers of the NICE public board meeting on 20 March 2024

  3. Public board meetings

    from previous meetings. Update from the Department of Health and Social Care Presented by: DHSC To receive an oral update on any issues...

  4. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued [GID-TA10416]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued [GID-TA10295]

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued [GID-TA10380]

    Technology appraisal guidance
    Discontinued

  7. Supporting family members, carers and staff:- What types of services or approaches are effective in supporting family members, carers and staffto be resilient and able to provide care and support to people with a learning disability and behaviour that challenges?

    supporting family members, carers and staffto be resilient and able to provide care and support to people with a learning disability and...

    Research recommendation
    Published
    15 November 2018

  8. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

    Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA292

  9. Bosutinib for previously treated chronic myeloid leukaemia (TA401)

    Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA401

  10. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    CG173/4 Question What are the key factors, including additional care and support, that influence participation* and quality of life in...

    Research recommendation
    Published
    26 October 2020

  11. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued [GID-TA10047]

    Technology appraisal guidance
    Discontinued

  12. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued [GID-MT563]

    Medical technologies guidance
    Discontinued

  13. Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

    Discontinued [GID-TA10221]

    Technology appraisal guidance
    Discontinued

  14. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA418

  15. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

    Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    18 February 2016
    View recommendations

    Sections for TA384